Skip to Main Content

INFORMATION FOR

A Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia

Conditions

Myeloid and Monocytic Leukemia

Phase I

What is the purpose of this trial?

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia

  • Trial with
    Celgene Corporation
  • Start Date
    08/14/2017
  • End Date
    08/01/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000020835